Your browser doesn't support javascript.
loading
Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia.
Ramos Elbal, Eduardo; Fuster, Jose Luis; Campillo, José A; Galera, Ana María; Cortés, Mar Bermúdez; Llinares, María Esther; Jiménez, Irene; Plaza, Mercedes; Martínez Banaclocha, Helios; Galián, José Antonio; Blanquer Blanquer, Miguel; Martínez Sánchez, María Victoria; Muro, Manuel; Minguela, Alfredo.
Affiliation
  • Ramos Elbal E; Pediatric Oncohematology Department, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Fuster JL; Pediatric Oncohematology Department, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Campillo JA; Immunology Service, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Galera AM; Pediatric Oncohematology Department, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Cortés MB; Pediatric Oncohematology Department, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Llinares ME; Pediatric Oncohematology Department, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Jiménez I; Pediatric Oncohematology Department, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Plaza M; Pediatric Oncohematology Department, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Martínez Banaclocha H; Immunology Service, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Galián JA; Immunology Service, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Blanquer Blanquer M; Haematology Service, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Martínez Sánchez MV; Immunology Service, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Muro M; Immunology Service, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Minguela A; Immunology Service, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain. alfredo.minguela@carm.es.
Clin Transl Oncol ; 26(1): 278-287, 2024 Jan.
Article in En | MEDLINE | ID: mdl-37368200
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Precursor Cell Lymphoblastic Leukemia-Lymphoma Type of study: Prognostic_studies Limits: Child / Humans Language: En Journal: Clin Transl Oncol Year: 2024 Type: Article Affiliation country: Spain
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Precursor Cell Lymphoblastic Leukemia-Lymphoma Type of study: Prognostic_studies Limits: Child / Humans Language: En Journal: Clin Transl Oncol Year: 2024 Type: Article Affiliation country: Spain